The path of upstream development is long and complex. The choices made during this time can strongly influence the success of a biologic candidate. Factors such as host cell line, media, and process scale-up considerations can influence product yield and quality. A solution that has co-optimized these factors is paramount for the proper and timely evaluation of biologics. We made additions to our platform that address the key impediments to cell line and process development. We will show the performance of multiple biologics as they travel through the cell line and process development processes.
In this webinar, you will learn:
- The key bottlenecks in cell line and upstream process development
- Novel technologies and products that overcome these impediments
- How an off-the-shelf solution can address your upstream needs
Speakers
Brandon Medeiros
Merck
Upstream Process Engineer
Brandon Medeiros is an upstream process engineer in our bioprocessing R&D organization. Since joining the company in February 2017, Brandon has led the Upstream Process Innovation Center which supports the organization through the development and production of industry-relevant cell culture processes. Prior to joining our company, Brandon worked in upstream process development for Merrimack Pharmaceuticals, Novartis Vaccines and Diagnostics, and EMD Serono. Brandon holds a B.S. in biology from Northeastern University.
Patricia Kumpey
Merck
Associate Scientist
Patricia (Tish) Kumpey is an associate upstream scientist. She has spent nearly 25 years in the bioprocess industry, optimizing upstream bioreactor conditions for mammalian and microbial systems. Tish has taken her knowledge of process development into the early steps of process development; namely, cell line development. By taking a holistic view of upstream bioprocessing, she hopes to alleviate current bottlenecks in upstream.
Pharma and biopharma manufacturing
- Cell Line Development
기간:34min
언어:English
세션 1:발표 완료 April 30, 2020
계속 읽으시려면 로그인하거나 계정을 생성하세요.
계정이 없으십니까?